Результаты поиска

Targeting the DNA Damage Response for Cancer Therapy.

Over the course of long-term evolution, cells have developed intricate defense mechanisms in response to DNA damage; these mechanisms play a pivotal role in maintaining genomic stability. Defects in the DNA damage response pathways can give rise to various diseases, including cancer. The DNA damage response (DDR) system is instrumental in safeguarding genomic stability. The accumulation of DNA damage and the weakening of DDR function both promote the initiation and progression of tumors. Simultaneously, they offer opportunities and targets for cancer therapeutics. This article primarily elucid

Совпадение в полном тексте источника
… The first reported ATM inhibitor, KU-55933, significantly enhanced sensitivity to IR and chemotherapeutic agents that induce DSBs, such as etoposide, doxorubicin, and camptothecin [ 87 ]. …

Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article.

Multiple myeloma (MM) is a hematologic malignancy characterized by the abnormal clonal proliferation of plasma cells that may result in focal bone lesions, renal failure, anemia, and/or hypercalcemia. Recently, the diagnosis and treatment of MM have evolved due to a better understanding of disease pathophysiology, improved risk stratification, and new treatments. The incorporation of new drugs, including proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies and high-dose chemotherapy followed by hematopoietic stem cell transplantation, has resulted in a significant improvement in

Совпадение в полном тексте источника
… 72 In the last two decades, melphalan use has generally decreased with the development of novel agents; however, it is still used at a high dosage as a conditioning regimen before ASCT, and it is also used in combination with dexamethasone, thalidomide, cisplatin, Adriamycin, cyclophosphamide, and etoposide …

Adding recombinant AAVs to the cancer therapeutics mix.

Gene therapy is a powerful biological tool that is reshaping therapeutic landscapes for several diseases. Researchers are using both non-viral and viral-based gene therapy methods with success in the lab and the clinic. In the cancer biology field, gene therapies are expanding treatment options and the possibility of favorable outcomes for patients. While cellular immunotherapies and oncolytic virotherapies have paved the way in cancer treatments based on genetic engineering, recombinant adeno-associated virus (rAAV), a viral-based module, is also emerging as a potential cancer therapeutic thr

Совпадение в полном тексте источника
… Drug family | Subtypes | Examples | Mechanism of action | Disadvantages Chemotherapy 13 , 14 , 15 , 16 , 17 | platinum agents, alkylating agents, topoisomerase inhibitors, antimetabolites, taxanes | carboplatin and cisplatin, cyclophosphamide, etoposide and doxorubicin, 5-fluorouracil and gemcitabine …

Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls.

BackgroundThis study aims to examine polypharmacy (PP) prevalence in patients with chronic kidney disease (CKD) Stage G4/G5 and patients with kidney replacement therapy (KRT) compared with matched controls from the general population. Furthermore, we examine risk factors for PP and describe the most commonly dispensed medications.MethodsDutch health claims data were used to identify three patient groups: CKD Stage G4/G5, dialysis and kidney transplant patients. Each patient was matched to two controls based on age, sex and socio-economic status (SES) score. We differentiated between 'all medic

Совпадение в полном тексте источника
… L01BB07 | Nelarabine L01BC01 | Cytarabine L01BC03 | Tegafur L01BC05 | Gemcitabine L01BC06 | Capecitabine L01BC07 | Azacitidine L01BC08 | Decitabine L01BC53 | Tegafur and Gimeracil and Oteracil L01BC59 | Trifluridine and Tipiracil L01CA01 | Vinblastine L01CA02 | Vincristine L01CA04 | Vinorelbine L01CB01 | Etoposide …

Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms.

Peripheral neurologic complications are frequent adverse events during oncologic treatments and often lead to dose reduction, administration delays with time elongation of the therapeutic plan and, not least, worsening of patients' quality of life. Experience skills are required to recognize symptoms and clinical evidences and the collaboration between different health professionals, in particular oncologists and hospital pharmacists, grants a correct management of this undesirable occurrence. Some classes of drugs (platinates, vinca alkaloids, taxanes) typically develop this kind of side effe

Совпадение в полном тексте источника
… Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients with Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group J. Clin. …

Current and Novel Alkylators in Multiple Myeloma.

A large number of novel treatments for myeloma have been developed and approved; however, alkylating drugs continue to be part of standard regimens. Additionally, novel alkylators are currently being developed. We performed a non-systematized literary search for relevant papers and communications at large conferences, as well as exploiting the authors' knowledge of the field, to review the history, current use and novel concepts around the traditional alkylators cyclophosphamide, bendamustine and melphalan and current data on the newly developed pro-drug melflufen. Even in the era of targeted

Совпадение в полном тексте источника
… One of the more noteworthy attempts was the VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide) regimen for induction and consolidation before transplant, in the total therapy 3 study [ 10 ], showing near-complete remission and 2-year survival rates …

Noninfectious pulmonary complications of haematopoietic stem cell transplantation.

Haematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant and nonmalignant conditions. Pulmonary complications, both infectious and noninfectious, are a major cause of morbidity and mortality in patients who undergo HSCT. Recent advances in prophylaxis and treatment of infectious complications has increased the significance of noninfectious pulmonary conditions. Acute lung injury associated with idiopathic pneumonia syndrome remains a major acute complication with high morbidity and mortality. On the other hand, bronchiolitis obliterans syndrome is

Совпадение в полном тексте источника
… Delayed pulmonary toxicity syndrome (DPTS) is primarily seen in autologous stem cell transplant populations who received conditioning regimens containing bleomycin, bortezomib, thalidomide, cyclophosphamide, bischloroethyl nitrosourea, cisplatin and etoposide [ 14 , 86 ]. …

Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.

The incidence and mortality of cancer have increased over the past decades. Significant progress has been made in understanding the underpinnings of this disease and developing therapies. Despite this, cancer still remains a major therapeutic challenge. Current therapeutic research has targeted several aspects of the disease such as cancer development, growth, angiogenesis and metastases. Many molecular and cellular mechanisms remain unknown and current therapies have so far failed to meet their intended potential. Recent studies show that glycans, especially oligosaccharide chains, may play a

Совпадение в полном тексте источника
… Additionally, endogenous Gal-3 may inhibit Cisplatin- or Etoposide-induced mitochondrial apoptosis pathway in prostate and breast cancer cells [ 84 , 89 ]. …

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… This trial ‘regrettably’ showed that improved OS and lower relapse risk were observed following TBI plus etoposide compared with chemotherapy-only conditioning. At this point in time, TBI plus etoposide must be recommended for patients >4 years old with high-risk ALL undergoing allo-HCT [ 263 ]. …

How histone modifications influence cellular radiosensitivity: Pharmaceutically targeting epigenetic regulators as a promising avenue to overcome radioresistance.

Cancer remains the leading cause of mortality worldwide. Radiotherapy (RT), a cornerstone of oncological treatment for over a century, has achieved great success in various cancers. However, radioresistance remains the primary factor leading to the failure of radiotherapy. Histone modifications in cancer cells are known to play a pivotal role in regulating radiosensitivity by modulating chromatin structure, either by loosening or tightening it. Here, we provide a comprehensive summary of the link between aberrant histone modifications and radiation resistance across various cancer and normal t

Advances in α-Lipoic Acid for Disease Prevention: Mechanisms and Therapeutic Insights.

α-Lipoic acid (ALA) is a naturally occurring compound with diverse biological functions, widely distributed in animal and plant tissues. It has attracted considerable attention due to its versatile therapeutic potential. However, despite these promising prospects, the clinical application of ALA remains limited by its low bioavailability and chemical instability and an incomplete understanding of its multifaceted mechanisms across various diseases. This review provides a comprehensive overview of the biochemical properties of ALA, including its direct free-radical-scavenging activity, regenera

Совпадение в полном тексте источника
… In combination with cisplatin, etoposide, and paclitaxel, ALA increased the sensitivity of lung cancer cells to apoptosis by downregulating integrin β1 and β3, which are related to invasive behavior and metastasis [ 50 ]. …

Клеточная терапия в многоразовом склерозе: Клинические достижения, ограничения и перспективы на будущее из клинических исследований - систематический обзор.

Фон: Множественный склероз (MS) — хроническое аутоиммунное демиелинирующее заболевание центральной нервной системы (CNS), характеризующееся воспалением, обезвоживанием и прогрессивным нейродегенерацией. Несмотря на то, что нынешняя медикаментозная терапия (ДМТ) может снизить частоту рецидивов и провокационной активности, они редко останавливают долгосрочное развитие или устраняют неврологические повреждения. В последние годы клеточная терапия стала многообещающим подходом к содействию иммунальному регулированию и нейрогенерации в MS. Методы: Настоящий обзор резюмирует текущие клинические данны

Совпадение в полном тексте источника
… AHSCT (Autologous Hematopoietic Stem Cell Transplantation), ARR (Annualized Relapse Rate), ATG (Anti-Thymocyte Globulin), BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), BSBMTCT (British Society of Blood and Marrow Transplantation and Cellular Therapy), CD (Confirmed Disability), CD34+ (Hematopoietic …

Recent Updates of PET in Lymphoma: FDG and Beyond.

Lymphoma is one of the most common cancers worldwide, categorized into Hodgkin lymphoma and non-Hodgkin lymphoma. 18F-fluorodeoxyglucose positron emission tomography (FDG PET) has become an essential imaging tool for evaluating patients with lymphoma in terms of initial diagnosis, staging, prognosis, and treatment response assessment. Recent advancements in imaging technology and methodologies, along with the development of artificial intelligence, have revolutionized the evaluation of complex imaging data, enhancing the diagnostic and predictive power of PET in lymphoma. However, FDG is not c

Совпадение в полном тексте источника
… For patients with positive iPET, the 5-year PFS improved from 77.4% with standard ABVD plus involved-node radiotherapy (INRT) to 90.6% with intensification to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) plus INRT ( p = 0.002 …

Safety of solid oncology drugs in older patients: a narrative review.

The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of comorbidities and frailty factors, this population is at higher risk of serious toxicity from anticancer drugs and, consequently, often under-treated. Despite the complexity of these treatments, a good knowledge of the pharmacology of anticancer drugs and potentially risky situations can limit the emergence of potentially lethal toxicities in this population. This review focuses on optimizing systemic oncology treatments f

Совпадение в полном тексте источника
… Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer. 1998;34(11):1710–1714. doi: 10.1016/s0959-8049(98)00207-x. 113. Launay-Vacher V., Janus N., Deray G. Renal insufficiency and cancer treatments. …

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.

Chimeric antigen receptor (CAR) T-cell therapy represents a highly efficacious treatment modality demonstrated to enhance outcomes in patients afflicted with malignancies, particularly those enduring relapsed or refractory hematological malignancies. However, the escalating adoption of CAR T-cell therapy has unveiled several life-threatening toxicities, notably cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and hematological toxicities (HTs), thereby hindering the broad implementation of CAR T-cell therapy. HTs encompass a spectrum

Совпадение в полном тексте источника
… If clinical or serological improvement not manifest within 48 h, consideration should be given to administering etoposide at doses of 75–100 mg/m 2 [ 121 , 122 ]. …

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.

The AML treatment landscape has significantly changed in recent years with the approval of targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of FLT3 and IDH1/2 mutations. More importantly, approval of the combination of the BCl-2 inhibitor, venetoclax, and hypomethylating agents or low dose cytarabine provided unprecedented breakthrough for the frontline treatment of older, unfit AML patients. Even with all this exciting progress, more targeted therapies for AML treatment are needed. Recent development of menin inhibitors targeting AML with KMT2A rearr

Совпадение в полном тексте источника
… However, the KMT2A r incidence is higher in other contexts, for example, in up to 70% of infantile leukemias and approximately 50% of therapy related AML (t-AML) following etoposide exposure [ 29 , 30 ].The translocation process is complex, with over 80 different partner genes identified, and research …

An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications.

Arsenic trioxide is a first-line treatment drug for acute promyelocytic leukemia, which is also effective for other kinds of leukemia. Its side effects, however, limit its clinical application, especially for patients with complex leukemia symptoms. Combination therapy can effectively alleviate these problems. This review summarizes the research progress on the combination of arsenic trioxide with anticancer drugs, vitamin and vitamin analogs, plant products, and other kinds of drugs in the treatment of leukemia. Additionally, the new progress in arsenic trioxide-induced cardiotoxicity was sum

Совпадение в полном тексте источника
… Adriamycin-resistant K-562 leukemia (K-562/RA) cells were cross-resistant to multiple agents (pirarubicin, daunorubicin, 5-FU, etoposide, vincristine and paclitaxel), with the exception of arsenic trioxide. …

The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies.

IntroductionImmunotherapy has revolutionized how cancer is treated. Many of these immunotherapies rely on ex vivo expansion of immune cells, classically T cells. Still, several immunological obstacles remain, including tumor impermeability by immune cells and the immunosuppressive nature of the tumor microenvironment (TME). Logistically, high costs of treatment and variable clinical responses have also plagued traditional T cell-based immunotherapies.MethodsTo review the existing literature on cellular immunotherapy, the PubMed database was searched for publications using variations of the phr

Совпадение в полном тексте источника
… These CDXs are created by taking CTCs from patients with SCLC and injecting the cells into immunocompromised mouse models. 116 When treated with etoposide and platinum therapies, the CDXs therapeutic response mirrored that of the patients from which the CTCs were taken ( Fig. 5 ). …

Multidisciplinary Approach to Spinal Metastases and Metastatic Spinal Cord Compression-A New Integrative Flowchart for Patient Management.

Metastatic spine disease (MSD) and metastatic spinal cord compression (MSCC) are major causes of permanent neurological damage and long-term disability for cancer patients. The development of MSD is pathophysiologically framed by a cooperative interaction between general mechanisms of bone growth and specific mechanisms of spinal metastases (SM) expansion. SM most commonly affects the thoracic spine, even though multiple segments may be affected concomitantly. The great majority of SM are extradural, while intradural-extramedullary and intramedullary metastases are less frequently seen. The ma

Совпадение в полном тексте источника
… double immunotherapy (ipilimumab + nivolumab) | Median OS is 45.7 months [ 79 ] Multiple myeloma | Bortezomib (proteasome inhibitor), lenalidomide, and dexamethasone (corticosteroid) | Median OS is 60 months [ 80 ] Testicular germ cell tumors | Platinum-based chemotherapy (e.g., bleomycin + cisplatin + etoposide …

The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage.

In recent years, the onco-nephrology field has acquired a relevant role in internal medicine due to the growing number of cases of renal dysfunction that have been observed in cancer patients. This clinical complication can be induced by the tumor itself (for example, due to obstructive phenomena affecting the excretory tract or by neoplastic dissemination) or by chemotherapy, as it is potentially nephrotoxic. Kidney damage can manifest as acute kidney injury or represent a worsening of pre-existing chronic kidney disease. In cancer patients, physicians should try to set preventive strategies

Совпадение в полном тексте источника
… The main chemotherapeutic agents, partially excreted through the kidney, are carboplatin, cisplatin, mitomycin, methotrexate, pemetrexed, pentostatin, topotecan, bleomycin, capecitabine and etoposide [ 112 ]. …